Myeloma News and Research

RSS

New discovery offers hope for overcoming CAR-T cell therapy resistance

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients.

12 Sep 2024

Study shows CAR T-cell therapy's risk of second primary malignancies comparable to other treatments

The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs following other standard-of-care therapies, according to a systematic review and meta-analysis.

11 Sep 2024

Cancer drug offers life-changing results for severe lupus patient

The team at Charité – Universitätsmedizin Berlin is astounded by the huge improvement seen in a female patient with severe systemic lupus erythematosus (SLE) after being treated with the cancer medication teclistamab. Not long ago, the 23-year-old was wheelchair-bound due to the autoimmune disease.

6 Sep 2024

New test detects cancer risk in type 2 diabetes patients

Individuals with type 2 diabetes who are at higher risk of certain cancers could be identified by a simple blood test, this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Madrid, 9-13 September) will hear.

28 Aug 2024

Exploring targeted therapies in the complex landscape of multiple myeloma

Multiple myeloma (MM) is a complex hematological malignancy with significant unmet needs. While conventional therapies have significantly improved patient survival, the disease remains incurable.

20 Aug 2024

Weill Cornell Medicine secures $12.4 million grant for lymphoma research

Weill Cornell Medicine has received a five-year, $12.4 million grant from the National Cancer Institute, part of the National Institutes of Health, for an extensive program of basic and translational research on the biology of diffuse large B-cell lymphoma (DLBCL), the most common form of lymphoma.

15 Aug 2024

New trial explores BAFF CAR T-cell therapy for relapsed myeloma

University Hospitals (UH) Seidman Cancer Center hematologist-oncologist Leland Metheny, MD, is leading the trial.

14 Aug 2024

New insights into retrotransposon-derived DNA zip codes in myeloma cells

A new editorial was published in Oncoscience (Volume 11) on July 13, 2024, entitled, "Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization."

9 Aug 2024

Using advanced CRISPR to boost efficiency of CAR-T cell therapies

CAR-T cells are highly effective in treating selected blood cancers. However, challenges remain with this new therapy, which was first approved in 2017 in the USA and a year later in Europe for treating acute lymphoblastic leukemia (ALL).

2 Aug 2024

Targeting oncogenic transcription factors to develop potential new cancer treatments

A new study from the University of Michigan Health Rogel Cancer Center furthers research that suggests the potential of developing new cancer treatments to target oncogenic transcription factors by indirectly affecting their ability to access enhancer DNA in chromatin.

30 Jul 2024

Researchers find the effect of pesticides on increased cancer risk is comparable to smoking for some cancers

Researchers comprehensively evaluated the impact of pesticide use on cancer development in the United States.

29 Jul 2024

Overcoming cancer relapse with CAR-Enhancer therapy

Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.

29 Jul 2024

Study highlights infection as major post-CAR-T therapy challenge

In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study published in Blood Advances.

25 Jul 2024

Simple blood test may predict CAR-T therapy success in multiple myeloma

A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy, according to new research from Weill Cornell Medicine, NewYork-Presbyterian, Columbia University and Icahn School of Medicine at Mount Sinai.

24 Jul 2024

Proteomic signatures enhance risk prediction for both common and rare diseases

Researchers have developed sparse prediction models combining plasma proteins and clinical data to predict the 10-year risk of 218 diseases. The study, involving over 41,000 participants, highlights the enhanced predictive power of proteomic signatures.

24 Jul 2024